Document:

Exhibit

EXHIBIT 10.34

DOLLAR TREE, INC.

OMNIBUS INCENTIVE PLAN

RESTRICTED STOCK UNIT AGREEMENT

(EXECUTIVE OFFICERS -- PERFORMANCE GOAL)

This RESTRICTED STOCK UNIT AGREEMENT (the “Agreement”), is effective as of the “Date of Grant” specified in the accompanying Notice of Grant, by and between Dollar Tree, Inc., a Virginia corporation, (the “Company”) and the “Grantee” as defined in the Notice of Grant.
W I T N E S S E T H:
The Dollar Tree, Inc. Omnibus Incentive Plan (the “Plan”) provides for the grant of Restricted Stock Units in accordance with the terms and conditions of the Plan, which are incorporated herein by reference.  The Company has determined that it is in the best interest of the Company and its shareholders to issue an Award of Restricted Stock Units to the Grantee.  Capitalized terms used in this Agreement and not otherwise defined herein or in the Notice of Grant have the meanings set forth in the Plan.
1.RESTRICTED STOCK UNITS.  The Company hereby grants the Grantee the number of Restricted Stock Units as set forth in the Notice of Grant subject to the terms, conditions and restrictions as set forth in the Plan, this Agreement and the Notice of Grant.  Each vested Restricted Stock Unit shall represent the right of the Grantee to receive one share of the Company’s Stock or the cash equivalent of the Fair Market Value of one share of the Company’s Stock determined on the applicable vesting date (or if the applicable vesting date is not a business day, then on the first business day preceding the applicable vesting date).  Except as otherwise provided in Section 3 below, the Restricted Stock Units will be settled by issuance of shares of Stock, or payment will be made, as soon as practicable after the date the Restricted Stock Units vest, but in no event later than the last day of the fiscal year in which the Restricted Stock Units vest.
2.VESTING AND TRANSFER RESTRICTIONS OF RESTRICTED STOCK UNITS.  The Restricted Stock Units shall become vested, if at all, and the restrictions described in Sections 2.1 and 2.2 shall lapse, as the Vesting Criteria set forth in the Notice of Grant are satisfied.
2.1.    Termination of Employment.  In the event of Grantee’s Termination of Employment with all Member Companies for any reason other than death, Disability or Retirement prior to the satisfaction of the Vesting Criteria, then the unvested Restricted Stock Units shall be forfeited as of the date of such Termination of Employment.  For purposes of this Agreement, “Termination of Employment” shall mean a “separation from service” as defined in Treasury Regulation § 1.409A-1(h) and “Member Company” shall mean a “service recipient” as defined in Treasury Regulation § 1.409A-1(h)(3).
2.2.    Transfer Restrictions.  Your Restricted Stock Units may not be transferred, assigned, pledged or hypothecated, whether by operation of law or otherwise, other than by will or by the laws of descent or distribution, and the provisions of this Agreement, the Plan and the Notice of Grant shall be binding upon the executors, administrators, heirs, and successors of the Grantee.  

Any levy of any execution, attachment or similar process upon the Restricted Stock Units, shall be null, void and without effect.  Notwithstanding the foregoing, Grantee may designate one or more beneficiaries for receipt of the shares of Stock subject to this Award upon Grantee’s death by delivering a beneficiary designation form to the Company.  A beneficiary designation will not become effective unless it is made on the form approved by the Company and is received by the Company prior to the Grantee’s death.
2.3.    Change in Control.  In the event of a Change in Control, Section 14 of the Plan shall apply to the Restricted Stock Units and the Committee may take such actions as it deems appropriate pursuant to the Plan, including accelerating vesting of the Awards by waiving all or part of the conditions for Vesting set forth in the Notice of Grant. Except as otherwise specifically provided below or in Section 3 of this Agreement, if the vesting of Restricted Stock Units is accelerated under this Section 2.3, such vested Restricted Stock Units shall be settled within 30 days of the date of the corporate action that accelerates vesting hereunder. Notwithstanding any provision to the contrary in this Agreement, in the event accelerated vesting of the Restricted Stock Units is required based on the terms of a retention agreement entered into by and between the Grantee and the Company prior to the Date of Grant, the Restricted Stock Units shall vest as required in such agreement and such vested Restricted Stock Units shall be settled or paid within 30 days of the Grantee’s Termination of Employment.
2.4.    Dividends.  No cash dividends shall be paid on the Restricted Stock Units.  
2.5.    Adjustments for Recapitalizations.  In the event of a Transaction (as defined in Section 4.5 of the Plan), the Restricted Stock Units shall be adjusted as set forth in Section 4.5 of the Plan and any additional securities or other consideration received pursuant to such adjustment shall be subject to the restrictions and risk of forfeiture to the same extent as the Restricted Stock Units with respect to which such securities or other consideration has been distributed.
3.DEATH, PERMANENT DISABILITY, OR RETIREMENT OF GRANTEE.
3.1.    Effect of Disability. In the event of Grantee’s Disability prior to an applicable vesting date for the Restricted Stock Units, the Service Requirements in the Notice of Grant shall be deemed satisfied; provided; however, that any vesting based on the Performance Goal included in the Vesting Criteria shall be satisfied solely to the extent certified by the Company as indicated in the Notice of Grant.  For purposes of this Agreement, “Disability” shall mean the Grantee has been determined to be disabled under the long-term disability insurance policy of the Company or the Company determines that a qualified medical professional has opined that the grantee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months; provided however, if the Grantee is eligible for Retirement, then “Disability” shall mean as defined under Code Section 409A(a)(2)(C) and the regulations promulgated thereunder, and the Grantee shall be deemed to have a Disability on the earliest date that the Grantee is determined to have a Disability either by the Company or as otherwise permitted under Treasury Regulation § 1.409A-3(i)(4)(iii).
3.2.    Death of Grantee.   In the event of the death of the Grantee, the Service Requirements in the Notice of Grant shall be deemed satisfied; provided; however, that any vesting based on the Performance Goal included in the Vesting Criteria shall be satisfied solely to the extent certified by the Company as indicated in the Notice of Grant.
3.3.    Retirement.  In the event of the Grantee’s Retirement, the Service Requirements in the Notice of Grant shall be deemed satisfied; provided; however, that any vesting based on the Performance Goal included in the Vesting Criteria shall be satisfied solely to the extent certified by the Company as indicated in the Notice of Grant.  For purposes of this Agreement, “Retirement” 

shall mean the Grantee’s Termination of Employment (a) on or after the date the Grantee attains the age of fifty-nine and a half (59 1⁄2) and (b) following at least seven (7) years of Service; provided that Retirement shall not include a termination for Cause before Retirement even if the requirements for Retirement are otherwise met.  Notwithstanding any provision of Section 1 or  Section 3.3 of the Agreement, in the event the Grantee is eligible for Retirement at the time the Committee exercises its discretion to accelerate vesting of all or part of the Restricted Stock Units due to a Change in Control as provided for in Section 2.3 of this Agreement, then the vested Restricted Stock Units shall be settled or payment made to the Grantee on the vesting dates set out in the Notice of Grant for the number of  Restricted Stock Units that would have otherwise vested on such vesting dates or, if earlier, on the date of the Grantee’s death, Disability or Termination of Employment.
4.SHAREHOLDER RIGHTS.  This Award of Restricted Stock Units does not entitle you to any rights as a shareholder of the Company unless and until the shares of Stock underlying the Award have been issued to you by registry in book-entry form with the Company.
5.ISSUANCE OF SHARES.  To the extent the Committee does not elect to settle the Restricted Stock Units in cash, the Company will issue the shares of Stock subject to the Restricted Stock Units as non‐certificated shares in book-entry form registered in Grantee’s name.  The purchase price of the shares of Stock is your Service to the Company during the vesting periods. The obligation of the Company to deliver shares of Stock upon the vesting of the Restricted Stock Units shall be subject to all applicable laws, rules, and regulations and such approvals by governmental agencies as may be deemed appropriate to comply with relevant state and federal securities laws and regulations and the rules of any applicable stock exchange.
6.CODE SECTION 409A.  To the extent this Agreement provides for a deferral of compensation subject to Code Section 409A and the regulations promulgated thereunder, this Agreement is intended to and shall be interpreted as necessary to comply with Code Section 409A.  In the event the Committee exercises its discretion to accelerate vesting of the Restricted Stock Units, then the vesting dates in the Notice of Grant shall be the specified payment dates under Treasury Regulation § 1.409A-3(a) for settlement or payment of the Restricted Stock Units.  Notwithstanding any other provision of this Agreement to the contrary, and solely to the extent required by Code Section 409A, in the event that Grantee is a “specified employee” under Code Section 409A(a)(2)(i) and the regulations promulgated thereunder on the date of Grantee’s Termination of Employment, then amounts payable under this Award due to Grantee’s Termination of Employment (other than for death) shall be accumulated and paid without interest to the Grantee on the first business day of the seventh month following the date of the Grantee’s Termination of Employment.
7.TAXES; WITHHOLDING OBLIGATION. 
7.1.    Generally. Grantee shall be ultimately liable and responsible for all taxes owed in connection with the Award, regardless of any action a Member Company takes with respect to any tax withholding obligations that arise in connection with the Award. The Member Companies make no representation or undertaking regarding the treatment of any tax withholding in connection with the grant or vesting of the Award or the subsequent sale of shares of Stock issuable pursuant to the Award. Neither the Company nor any Member Company is committed or under any obligation to structure the Award to reduce or eliminate Grantee’s tax liability.
7.2.    Payment of Withholding Taxes. 
7.2.1.    Prior to any event in connection with the Award (e.g., vesting) that the Company determines may result in any domestic or foreign tax withholding obligation, whether national, federal, state or local, including any employment or social tax obligation (the “Tax 

Withholding Obligation”), Grantee must arrange for the satisfaction of the amount of such Tax Withholding Obligation in a manner acceptable to the Company. 
7.2.2.    Unless Grantee chooses to satisfy the Tax Withholding Obligation by some other means in accordance with Section 7.2.3. below, Grantee’s acceptance of this Award constitutes Grantee’s instruction and authorization to the Company, and any brokerage firm determined acceptable to the Company for such purpose, to sell on Grantee’s behalf (including to the Company or any affiliate of the Company through the retention of a portion of the shares of Stock) a whole number of shares of Stock from those shares of Stock issuable to Grantee as the Company determines to be appropriate to generate cash proceeds sufficient to satisfy the Tax Withholding Obligation. Such shares of Stock will be sold on the day the Tax Withholding Obligation arises or as soon thereafter as practicable. If applicable, Grantee will be responsible for all brokers’ fees and other costs of sale, and agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale. To the extent the proceeds of such sale exceed Grantee’s Tax Withholding Obligation, the Company agrees to pay such excess in cash to Grantee through payroll as soon as practicable. Grantee acknowledges that the Company or its designee is under no obligation to arrange for such sale at any particular price, and that the proceeds of any such sale may not be sufficient to satisfy your Tax Withholding Obligation. Accordingly, Grantee agrees to pay to the Company (or Member Company as applicable) as soon as practicable, including through additional payroll withholding, any amount of the Tax Withholding Obligation that is not satisfied by the sale of shares of Stock described above. 
7.2.3.    At any time not less than five (5) business days before any Tax Withholding Obligation arises Grantee may elect to satisfy his or her Tax Withholding Obligation by delivering to the Company (or Member Company as applicable) an amount that the Company determines is sufficient to satisfy the Tax Withholding Obligation by (i) wire transfer to such account as the Company may direct, (ii) delivery of a certified check payable to the Company (or Member Company as applicable), or (iii) such other means as the Company may establish or permit. 
7.2.4.    The Company may refuse to issue any shares of Stock to Grantee until Grantee satisfies the Tax Withholding Obligation. To the maximum extent permitted by law, the Company has the right to retain, without notice, from shares of Stock issuable under the Award or from salary or other amounts payable to Grantee, shares of Stock or cash having a value sufficient to satisfy the Tax Withholding Obligation.
8.NO EMPLOYMENT RIGHTS.  Nothing in this Agreement shall affect in any manner whatsoever the right or power of a Member Company to terminate Grantee’s employment for any reason, with or without Cause.
9.MISCELLANEOUS.
9.1.    Governing Law.  This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the Commonwealth of Virginia, without giving effect to choice of law provisions thereof.  The Circuit Court of the City of Norfolk, Virginia, and the United States District Court, Eastern District of Virginia, Norfolk Division shall be the exclusive courts of jurisdiction or venue for any litigation, special proceedings or other proceedings between the parties that my be brought, or arise out of, in connection with, or by reason of this Agreement and the parties to this Agreement hereby consent to the jurisdiction of such courts.
9.2.    Entire Agreement; Enforcement of Rights.  The Plan and the Notice of Grant are hereby incorporated by reference in this Agreement.  This Agreement (including the Plan and the Notice of Grant) sets forth the entire agreement and understanding of the parties relating to the subject matter herein.  No modification of or amendment to this Agreement, nor any waiver of any 

rights under this Agreement, shall be effective unless in a writing signed by the Company and the Grantee to this Agreement.  The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.
9.3.    Severability.  If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith.  In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its terms.
9.4.    Notices.  Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient when delivered personally or sent by telegram or fax or forty-eight (48) hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written notice.
9.5.    Successors and Assigns.  The rights and benefits of this Agreement shall inure to the benefit of, and be enforceable by the Company’s successors and assigns.  The rights and obligations of Grantee under this Agreement may only be assigned with the prior written consent of the Company.
9.6.    Disclosure of Information.  In the event the Committee determines that the Grantee has materially violated the provisions of this Section 9.6, the Grantee shall immediately forfeit all unvested Restricted Stock Units.  The Grantee recognizes and acknowledges that the Company’s trade secrets, confidential information, and proprietary information, including customer and vendor lists and computer data and programs (collectively “Confidential Information”), are valuable, special and unique assets of the Company’s business, access to and knowledge of which are essential to the performance of the Grantee’s duties. The Grantee will not, before or after his date of Termination of Employment, in whole or in part, disclose such Confidential Information to any person or entity or make such Confidential Information public for any purpose whatsoever, nor shall the Grantee make use of such Confidential Information for the Grantee’s own purposes or for the benefit of any person or entity other than the Company under any circumstances before or after the Grantee’s date of Termination of Employment; provided that this prohibition shall not apply after the Grantee’s date of Termination of Employment to Confidential Information that has become publicly known through no action of the Grantee. The Grantee shall consider and treat as the Company’s property all memoranda, books, records, papers, letters, computer data or programs, or customer lists, including any copies thereof in human- or machine-readable form, in any way relating to the Company’s business or affairs, financial or otherwise, whether created by the Grantee or coming into his or her possession, and shall deliver the same to the Company on the date of Termination of Employment or, on demand of the Company, at any earlier time.ex-10.1

 Distribution Agreement
 This agreement is between Live Current Media, Inc. (“LIVC” or “Distributor”) located at 880 – 50 West Liberty Street, Reno, NV  89501, and Cell MedX Corp. (“CMXC” or “Lessor”) located at 123 W. Nye Ln, Suite 446 Carson City, NV.  For purposes of this agreement, LIVC and CMXC are referred to collectively as “the Parties.”
 Background
 WHEREAS, CMXC is the manufacturer of a microcurrent medical Device, namely the eBalanceTM Device and;
 WHEREAS, CMXC has identified two distribution market channels for sales of the eBalanceTM  Device, home based and individual rights (“Direct Rights”) and clinic, doctor and practitioner rights (“Wholesale Rights”) to use the eBalanceTM  Device to offer Sessions to clients;
 WHEREAS, CMXC now seeks to sell the worldwide Direct Rights to the eBalanceTM  Device and LIVC wishes to purchase these rights; 
 NOW, THEREFORE, in consideration of the mutual promises expressed herein, the sufficiency of which is acknowledged by the Parties, LIVC and CMXC agree as follows:
 Definitions
 1.
 In this agreement:
 (a)
 Device means any microcurrent device that CMXC, manufactures or acquires for therapeutic or other use anywhere in the Territory, any microcurrent device that CMXC develops for personal use by individual users in the Territory, and manuals for the operation of the Device.
 (b)
 Direct Rights means the rights to sell the Device directly to households and end users for personal use.
 (c)
 Distributor means Live Current Media Inc., a Nevada corporation located at 880 – 50 West Liberty Street, Reno, NV  89501.
 (d)
 Effective Date means a date on which both parties agree that the Device is a Saleable Device as defined in this section and also following a date on which the Device has received its 510k from the United States FDA .
 (e)
 License Fee means the fee paid by Distributor to CMXC for each Device to be distributed by Distributor.
 (f)
 Products includes any ancillary product (such as electrolyte, tools attachable to a Device for any purpose, and any other item that is used for the delivery of a Session) that CMXC produces or offers for distribution or sale (either directly or indirectly through a subsidiary) to Distributor that Distributor then distributes to a User. 
 (g)
 Saleable Device is a device that in addition to the ebalance software and capabilities, includes a disclaimer before each Session, a red/yellow/green graph and has the ability to accept credit card payments that are connected to automatically activating the monthly subscription or increase the Sessions on the Device.
 

 
 2
 

 

 (h)
 Session means a single Session or partial Session for “Wellness” or “Pain Management” or other Session program that may be added to the Device at any time with a Device that is provided to or administered by a User.
 (i)
 Term means the period of time from the Effective Date to the date that is 5 years after the Effective Date and automatically renewable for one year periods thereafter unless terminated earlier by either party under the provisions of this Agreement.
 (j)
 Territory means the whole world.
 (k)
 User includes any clinic, health practitioner, end user, other entity or person who has a Device for any use who enters into a lease agreement with CMXC for a Device through the Distributor. 
 (l)
 User Fees means the fees that CMXC charges a User for a Session from CMXC, net of any discounts, refunds or other reductions in gross fees. 
 (m)
 Wholesale Rights means the rights to sell the Device to clinics, doctors and practitioners whereby they will sell Sessions by the Device to their clients.
 2.
 All references to dollar amounts are in US dollars unless otherwise stated.
 Distribution licence
 3.
 CMXC grants to Distributor the exclusive Direct Rights to distribute Devices and Products to potential Users in the Territory as of the Effective Date on behalf of CMXC as the Lessor of the Devices.
 4.
 To secure this distribution licence, Distributor has paid a deposit of $250,000 to CMXC on signing of an LOI on September 10, 2018.  
 5.
 To maintain the exclusive distribution licence, Distributor must:
 (a)
 Order a minimum of 2,000 Devices as follows: 
 (i)
 a minimum of 500 Devices at the end of 14 months commencing on the Effective Date, 
 (ii)
 a minimum of 2,000 Devices at the end of 24 months commencing on the Effective Date; and
 (b)
 require that all of its Users buy all of the Products required for the delivery of a Session exclusively from Distributor; and
 (c)
 buy all of the Products required for Users under subparagraph (b) above exclusively from CMXC; and
 (d)
 24 months after the Effective Date be generating minimum User Fees equal to $100,000 to CMXC per month, regardless of whether its Users have generated this amount; and
 (e)
 In the event that LIVC does not meet the minimum order requirements as set out in this section, LIVC will maintain the right to continue to sell the Device on the same terms governed by this agreement other than that LIVC will lose the right to exclusivity.  If CMXC decides to sell the exclusive rights to any portion of the Territory at any time after this occurs, LIVC will no longer have the right to sell the device in that portion of the Territory; and
 

 
 3
 

 

 (f)
 In the event that LIVC does not meet the minimum purchase requirements as set out in this section, LIVC will continue to receive User Fees collected resulting from all sales made to the date of this event occurring on the same terms as this agreement but will lose exclusivity rights. If the rights are sold to a third party LIVC and CMXC will negotiate, in good faith, a fee payable to LIVC for the existing clients setup by LIVC in the territory which may also include the third party.
 6.
 Distributor has the right to sell the Device under the Wholesale Rights in any territory that has not been granted to a distributor by CMXC.  In addition, the Distributor has the first right of refusal to match any offer to purchase a Wholesale Right from CMXC for fifteen days after being notified. In the case the Wholesale Rights are sold to a third party LIVC and CMXC will negotiate, in good faith, a fee payable to LIVC for the existing clients setup by LIVC in the territory as part of the third party agreement.  It is acknowledged that at the signing of this Agreement, no Wholesale Rights have been granted by CMXC.
 7.
 At any time that CMXC is approached by a potential distributor which wishes to distribute or buy the Direct Rights to exclusively distribute the device in any country, CMXC will introduce the interested party to LIVC and LIVC will negotiate in good faith to sign a distribution arrangement that is economically beneficial to all parties.  These negotiations will be based on economic and financial criteria.
 8.
 Distributor may incorporate wholly owned subsidiary companies to perform this agreement in specific areas of the Territory; and may, with the written consent of CMXC, not to be unreasonably withheld, sub-license the distributorship authorized by this agreement to distributors in specific areas of the Territory.
 9.
 Nothing in this agreement transfers title of a Device to Distributor or a User. CMXC at all times owns the Devices and is entitled to all incidents of ownership. Distributor may not sell a Device without the written consent of CMXC.
 Licence Fee
 10.
 Distributor will pay to CMXC a Licence Fee equal to the retail cost of the Device less 20%, on the following schedule and terms:
 (a)
 50% of the Licence Fee when Distributor places a written order for Devices by e-mail or other method to be determined by CMXC; and
 (b)
 the remaining 50% of the Licence Fee on the specified delivery date; and
 (c)
 the Licence Fee for the current  Device will  not exceed $2,400 in the first 24 months of this agreement; and
 (d)
 Both Parties acknowledge that the price of new Devices developed in the future may be higher than the current price structure for the Device; and
 (e)
 Distributor and CMXC intend to offer a 90-day, money back guarantee less shipping and handling.  Each party is responsible for returning to buyers the funds they received from the original purchase; and
 (f)
 The retail cost will be subject to change at the sole discretion of CMXC on providing 30 days of written notice of any such change.
 

 
 4
 

 User Fees
 11.
 User Fees will:
 (a)
 be $240 per month  for households and personal use end users on a monthly fee basis which will include at least 50 Sessions; and
 (b)
 be split 50/50 between the Distributor and CMXC; and
 (c)
 CMXC may set different User Fees in certain circumstances 
 12.
 CMXC and the Distributor will agree on which company is to collect User Fees and the proceeds for the month will be distributed 15 days after the month end. 
 13.
 All credit card fees will be the responsibility of LIVC.
 14.
 Distributor or CMXC, at their own expense, may audit each others Sales and User Fee records—the calculations, invoices, receipts and any other record relating to Sales and User Fees—at any time upon 30 days written notice to the other Party.
 Device shipping, warranty and damage
 15.
 CMXC will ship, at its cost, all orders of Devices and Products to Distributor under this agreement, whether its own warehouse, a drop shipper or other distribution centre of Distributor’s choosing.  LIVC will be responsible for shipping to the end User.
 16.
 Distributor will replace any defective or damaged Device it has distributed to a User. Distributor will inform CMXC in writing of the serial number and location of the defective or damaged Device and request a replacement Device. Distributor will return the defective or damaged Device to CMXC. CMXC will ship the replacement Device with the next Device shipment order placed by LIVC.
 17.
 All defective Devices will be replaced at CMXC’s cost.
 18.
 Devices that have been physically damaged will not be guaranteed by the Distributor or CMXC.
 19.
 CMXC will maintain an adequate inventory of Devices to ensure timely delivery of new Devices and CMXC and LIVC will maintain a number of Devices necessary to ensure the timely replacement of defective Devices.
 Marketing plan and sales materials
 20.
 Distributor is responsible for producing its own marketing plan and sales materials. CMXC will provide all reasonable information that the Distributor requires for this purpose. Distributor will submit all sales and marketing materials to CMXC for review and approval by CMXC and will not use any such materials that have not been approved in advance by CMXC.
 21.
 Distributor will use its best efforts to acquire, in a timely manner, all distribution and marketing licences needed to operate in each of the countries where it distributes the Device, in order that it can collect funds directly from users.
 Referrals and in-house sales
 22.
 CMXC expects that it will receive requests for Devices  directly from potential Users, of the Direct Rights, within the Territory. All such requests will be referred to Distributor with the following exception:
 

 
 5
 

 CMXC will be able to sell and deliver Devices directly to individuals under the Direct Rights clause if those Devices have been sold through professional health care practitioners such as clinicians or Doctors.  These orders must be supported by documentation signed by the practitioner acknowledging that he/she is recommending purchase of the Device.  In addition, the health care practitioner must be receiving a commission for the referral of the sale to clients.  The audit rights of clause 14 are designed to manage this process.
 Termination
 23.
 Either Party may terminate this Agreement:
 (a)
 for cause upon the other Party’s breach or default of any provision of this Agreement unless such breach or default is corrected or cured within thirty (30) days after receipt of written notice thereof from the non-breaching Party; and
 (b)
 for cause immediately, in the event that the other Party: (i) is the subject of a voluntary or involuntary petition in bankruptcy; (ii) is or becomes insolvent; or, (iii) ceases to pay its obligations or conduct business in the normal course; and
 (c)
 for cause upon findings that the other Party misrepresented any provision of this Agreement; and
 (d)
 by mutual written consent.
 Representations and Warranties
 24.
 The Parties represent:
 CMXC represents and warrants that:
 (a)
 It is duly formed and in good standing under the laws of Nevada, it has the right to make and perform this agreement, and this agreement has been duly authorized by its board of directors, and
 (b)
 it has no agreement with any party that conflicts or could conflict with this agreement, and
 (c)
 the device is electrically certified for home use, hospital use and clinic use.
 Distributor represents and warrants that:
 (d)
 It is duly formed and in good standing under the laws of Nevada, it has the right to make and perform this agreement, and this agreement has been duly authorized by its board of directors, and
 (e)
 it has no agreement with any party that conflicts or could conflict with this agreement.
 

 Other terms
 25.
 The parties at all times will act in good faith to enable the other to perform this agreement and to resolve any disputes that might arise in the interpretation or performance of this agreement.
 26.
 Time is of the essence of this agreement and any amendment to it.
 27.
 If either party must perform under this agreement on a day that is not a business day in Vancouver BC, then the party must perform on the next business day in Vancouver, BC.
 

 
 6
 

 28.
 Notice:
 (a)
 Any notice or other document that must be given under this agreement must be in writing and signed by the appropriate authority and delivered by hand or overnight courier or transmitted by fax or email or other agreed electronic means to the following address, fax number or email address:  
 (i)
 To CMXC at_820 – 1130 West Pender Street , Vancouver, BC V6E 4A4; email: yana@cellmedx.com
 (ii)
 To Distributor at 820 – 1130 West Pender Street, Vancouver, BC  V6E 4A4; email:  david@livecurrent.com
 (b)
 Notice is deemed to have been received when it is delivered or transmitted if it is delivered or transmitted between 8:00 and 17:00 hours in Vancouver, BC and on the next business day if it is delivered or transmitted outside of these hours.
 29.
 This agreement is the entire agreement between the parties; and its terms may be waived or amended only in writing.  No waiver of any term operates to waive any other term.
 30.
 This agreement and any documentation or other information disclosed by one party to the other during their negotiations are confidential between the parties and may only be disclosed to others by either party if required by a regulatory agency with jurisdiction, such as, for example and without limitation, a securities commission and Health Canada.
 31.
 This agreement does not create a partnership or joint venture or any other kind of business association between the parties; and neither party has the power to bind the other in any way.
 32.
 Neither party may assign its interest in this agreement without the other party’s written consent, which cannot be unreasonably withheld.
 33.
 This agreement is binding on and inures to the benefit of the parties and their respective successors and permitted assigns.
 34.
 Each party participated in the drafting of this agreement; therefore, no presumption that either party or any other party drafted it applies in any interpretation, construction, or enforcement of this agreement.
 35.
 This agreement must be construed in accordance only with the laws of British Columbia and the parties must submit to the jurisdiction of the courts of British Columbia.
 36.
 No finding by a court of competent jurisdiction that any provision of this agreement is invalid, illegal, or otherwise unenforceable operates to impair or affect the remaining provisions which remain effective and enforceable.
 37.
 This agreement may be signed in counterparts and delivered to the parties by the means described in paragraph 28; and the counterparts together are deemed to be one original document.
 

 

 
 7
 

 

 THE PARTIES’ SIGNATURES below are evidence of their agreement to the foregoing 37 terms and conditions.
 

 	 	 	
	 Cell MedX Corp.
	  
	 Live Current Media Inc.

	  
	  
	  

	  
	  
	  

	 /s/ Frank McEnulty
	  
	 /s/ David Jeffs

	 Frank McEnulty, CEO and President
	  
	 David Jeffs

	  
	  
	  

	 Date:  March 21, 2019
	  
	 Date:  March 21, 2019

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]